1-9 of 9
J. Blake Bartlett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 2852.
https://doi.org/10.1182/blood-2021-149028
Published: 2021
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Larry D. Anderson, Jr., Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2723.
https://doi.org/10.1182/blood-2021-148533
Published: 2021
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Jacob P. Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 79.
https://doi.org/10.1182/blood-2021-149024
Published: 2021
Journal Articles

The Anti-Proliferative Effect of Lenalidomide On MM Cells in Vitro Is Ameliorated by Prior Exposure to Pomalidomide, An Agent with Activity against Lenalidomide Resistant MM Cells.

Mary Adams, Peter Schafer, J. Blake Bartlett
Journal: Blood
Blood (2009) 114 (22): 4926.
https://doi.org/10.1182/blood.V114.22.4926.4926
Published: 2009
Journal Articles

Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes.

Ling-Hua Zhang, Mary Adams, Jolanta Kosek, Peter H Schafer, J. Blake Bartlett
Journal: Blood
Blood (2009) 114 (22): 2855.
https://doi.org/10.1182/blood.V114.22.2855.2855
Published: 2009
Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 3473.
https://doi.org/10.1182/blood.V110.11.3473.3473
Published: 2007
Journal Articles

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Lei Wu, MD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2006) 108 (11): 3714.
https://doi.org/10.1182/blood.V108.11.3714.3714
Published: 2006
Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD
Journal: Blood
Blood (2005) 106 (11): 3959.
https://doi.org/10.1182/blood.V106.11.3959.3959
Published: 2005